Generation of tailored aerosols for inhalative drug delivery employing recent vibrating-mesh nebulizer systems

Therapeutic Delivery

Volumn 6, Issue 5, 2015, Pages 223-238

  Bohr, Adam ^a   Beck Broichsitter, Moritz ^a  

^a UNIV PARIS SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CITRATE SODIUM; CORTICOSTEROID; CYCLOSPORIN A; EXCIPIENT; LIPOSOME; SALBUTAMOL SULFATE; AEROSOL;

AEROSOL; BREATHING PATTERN; CAPILLARY BLOOD; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG INDUSTRY; DRY POWDER INHALER; HUMAN; INHALATION; JET NEBULIZER; LIPOPHILICITY; LIPOSOMAL DELIVERY; LUNG; LUNG ALVEOLUS; MEDICAL NEBULIZER; METERED DOSE INHALER; NEBULIZATION; NEBULIZER; PRIORITY JOURNAL; RESPIRATORY SYSTEM; REVIEW; ULTRASONIC NEBULIZER; ULTRASOUND; VISCOSITY; ADMINISTRATION AND DOSAGE; ANATOMY AND HISTOLOGY; CHEMISTRY; DEVICES; INHALATIONAL DRUG ADMINISTRATION; PARTICLE SIZE; PATHOPHYSIOLOGY; VIBRATION;

ADMINISTRATION, INHALATION; AEROSOLS; DRUG DELIVERY SYSTEMS; HUMANS; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; RESPIRATORY SYSTEM; VIBRATION;

EID: 84929754475     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.15.18     Document Type: Review

References (157)

1. Groneberg DA, Witt C, Wagner U, Chung KF, Fischer A. Fundamentals of pulmonary drug delivery. Respir. Med. 97, 382-387 (2003).
2. Rau JL. The inhalation of drugs: advantages and problems. Respir. Care 50, 367-382 (2005).
3. Ruge CA, Kirch J, Lehr CM. Pulmonary drug delivery: from generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges. Lancet Respir. Med. 1, 402-413 (2013).
4. Hickey AJ. Controlled delivery of inhaled therapeutic agents. J. Control Release 190, 182-188 (2014).
5. Chow AH, Tong HH, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary drug delivery. Pharm. Res. 24, 411-437 (2007).
6. Courrier HM, Butz N, Vandamme TF. Pulmonary drug delivery systems: recent developments and prospects. Crit. Rev. Ther. Drug Carrier Syst. 19, 425-498 (2002).
7. Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet 377, 1032-1045 (2011).
8. Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc. Am. Thorac. Soc. 1, 315-320 (2004).
9. Carvalho TC, Peters JI, Williams RO 3rd. Influence of particle size on regional lung deposition - what evidence is there? Int. J. Pharm. 406, 1-10 (2011).
10. Hofmann W. Modelling inhaled particle deposition in the human lung - a review. J. Aerosol Sci. 42, 693-724 (2011).
11. Anderson PJ. History of aerosol therapy: liquid nebulization to MDIs to DPIs. Respir. Care 50, 1139-1150 (2005).
12. Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir. Care 47, 1406-1418 (2002).
13. Steckel H, Eskandar F. Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers. Eur. J. Pharm. Sci. 19, 443-455 (2003).
14. Waldrep JC, Dhand R. Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation. Curr. Drug Deliv. 5, 114-119 (2008).
15. Watts AB, McConville JT, Williams RO 3rd. Current therapies and technological advances in aqueous aerosol drug delivery. Drug Dev. Ind. Pharm. 34, 913-922 (2008).
16. Beck-Broichsitter M, Kleimann P, Schmehl T et al. Impact of lyoprotectants for the stabilization of biodegradable nanoparticles on the performance of air-jet, ultrasonic, and vibrating-mesh nebulizers. Eur. J. Pharm. Biopharm. 82, 272-280 (2012).
17. Zhou QT, Tang P, Leung SS, Chan JG, Chan HK. Emerging inhalation aerosol devices and strategies: where are we headed? Adv. Drug Deliv. Rev. 75, 3-17 (2014).
18. Martin AR, Finlay WH. Nebulizers for drug delivery to the lungs. Expert Opin. Drug Deliv. doi:10.1517/17425247.174217995087 (2014) (Epub ahead of print).
19. Ghazanfari T, Elhissi AM, Ding Z, Taylor KM. The influence of fluid physicochemical properties on vibrating-mesh nebulization. Int. J. Pharm. 339, 103-111 (2007).
20. Zhang G, David A, Wiedmann TS. Performance of the vibrating membrane aerosol generation device: Aeroneb micropump nebulizer. J. Aerosol Med. 20, 408-416 (2007).
21. Beck-Broichsitter M, Knuedeler MC, Seeger W, Schmehl T. Controlling the droplet size of formulations nebulized by vibrating-membrane technology. Eur. J. Pharm. Biopharm. 87, 524-529 (2014).
22. Yu J, Chien YW. Pulmonary drug delivery: physiologic and mechanistic aspects. Crit. Rev. Ther. Drug Carrier Syst. 14, 395-453 (1997).
23. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56, 588-599 (2003).
24. Cone RA. Barrier properties of mucus. Adv. Drug Deliv. Rev. 61, 75-85 (2009).
25. Fahy JV, Dickey BF. Airway mucus function and dysfunction. N. Engl. J. Med. 363, 2233-2247 (2010).
26. Lopez-Rodriguez E, Perez-Gil J. Structure-function relationships in pulmonary surfactant membranes: from biophysics to therapy. Biochim. Biophys. Acta 1838(6), 1568-1585 (2014).
27. Parra E, Perez-Gil J. Composition, structure and mechanical properties define performance of pulmonary surfactant membranes and films. Chem. Phys. Lipids 185, 153-175 (2015).
28. Gehr P, Green F, Geiser M, Im Hof V, Lee NM, Schürch S. Airway surfactant, a primary defense barrier: mechanical and immunological aspects. J. Aerosol Med. 9, 163-181 (1996).
29. Geiser M. Update on macrophage clearance of inhaled micro- and nanoparticles. J. Aerosol Med. 23, 207-217 (2010).
30. Rudolf G, Köbrich R, Stahlhofen W, James AC. Regional aerosol deposition in man - a statistical and algebraic model. Ann. Occup. Hyg. 38(S1), 1-14 (1994).
31. Roth AP, Lange CF, Finlay WH. The effect of breathing pattern on nebulizer drug delivery. J. Aerosol Med. 16, 325-339 (2003).
32. Cheng YS. Mechanisms of pharmaceutical aerosol deposition in the respiratory tract. AAPS PharmSciTech. 15, 630-640 (2014).
33. Heyder J, Gebhart J, Rudolf G, Schiller CF, Stahlhofen W. Deposition of particles in the human respiratory tract in the size range 0.005-015 μm. J. Aerosol Sci. 17, 811-825 (1986).
34. Schiller CF, Gebhardt J, Heyder J, Rudolf G, Stahlhofen W. Deposition of monodisperse insoluble aerosol particles in the 0.005 to 0.2 μm size range within the human respiratory tract. Ann. Occup. Hyg. 32, 41-49 (1988).
35. Beck-Broichsitter M, Merkel OM, Kissel T. Controlled pulmonary drug and gene delivery using polymeric nanocarriers. J. Control Release 161, 214-224 (2012).
36. Finlay WH, Martin AR. Recent advances in predictive understanding of respiratory tract deposition. J. Aerosol Med. 21, 189-205 (2008).
37. Finlay WH. Estimating the type of hygroscopic behavior exhibited by aqueous droplets. J. Aerosol Med. 11, 221-229 (1998).
38. Finlay WH, Stapleton KW, Zuberbuhler P. Errors in regional lung deposition predictions of nebulized salbutamol sulphate due to neglect or partial inclusion of hygroscopic effects. Int. J. Pharm. 149, 63-72 (1997).
39. Finlay WH, Stapleton KW, Chan HK, Zuberbuhler P, Gonda I. Regional deposition of inhaled hygroscopic aerosols: in vivo SPECT compared with mathematical modeling. J. Appl. Physiol. 81, 374-383 (1996).
40. Fleming JS, Epps BP, Conway JH, Martonen TB. Comparison of SPECT aerosol deposition data with a human respiratory tract model. J. Aerosol Med. 19, 268-278 (2006).
41. Patton JS, Brain JD, Davies LA et al. The particle has landed-characterizing the fate of inhaled pharmaceuticals. J. Aerosol Med. 23, S71-S87 (2010).
42. de Souza Carvalho C, Daum N, Lehr CM. Carrier interactions with the biological barriers of the lung: advanced in vitro models and challenges for pulmonary drug delivery. Adv. Drug Deliv. Rev. 75, 129-140 (2014).
43. Cazzola M, Rogliani P, Novelli L, Matera MG. Inhaled corticosteroids for chronic obstructive pulmonary disease. Expert Opin. Pharmacother. 14, 2489-2499 (2013).
44. Louie S, Zeki AA, Schivo M et al. The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations. Expert Rev. Clin. Pharmacol. 6, 197-219 (2013).
45. Ehrick JD, Wylie J, Goodey AP, Li Y, Liu O, Donovan B. Orally inhaled fixed-dose combination products for the treatment of asthma and chronic obstructive pulmonary disease: not simple math. Ther. Deliv. 5, 297-317 (2014).
46. Scheuch G, Kohlhaeufl MJ, Brand P, Siekmeier R. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv. Drug Deliv. Rev. 58, 996-1008 (2006).
47. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 6, 67-74 (2007).
48. Hickey AJ. Back to the future: inhaled drug products. J. Pharm. Sci. 102, 1165-1172 (2013).
49. Mortensen NP, Hickey AJ. Targeting inhaled therapy beyond the lungs. Respiration 88, 353-354 (2014).
50. Schürch S, Gehr P, Im Hof V, Geiser M, Green F. Surfacntant displaces particles toward the epithelium in airways and alveoli. Respir. Physiol. 80, 17-32 (1990).
51. Geiser M, Schurch S, Gehr P. Influence of surface chemistry and topography of particles on their immersion into the lung's surface-lining layer. J. Appl. Physiol. 94, 1793-1801 (2003).
52. Lai SK, Wang YY, Wirtz D, Hanes J. Micro- and macrorheology of mucus. Adv. Drug Deliv. Rev. 61, 86-100 (2009).
53. Sanders N, Rudolph C, Braeckmans K, De Smedt SC, Demeester J. Extracellular barriers in respiratory gene therapy. Adv. Drug Deliv. Rev. 61, 115-127 (2009).
54. van der Schans CP. Bronchial mucus transport. Respir. Care 52, 1150-1158 (2007).
55. Ruge CA, Kirch J, Canadas O et al. Uptake of nanoparticles by alveolar macrophages is triggered by surfactant protein A. Nanomedicine 7, 690-693 (2011).
56. Schleh C, Rothen-Rutishauser BM, Blank F et al. Surfactant protein D modulates allergen particle uptake and inflammatory response in a human epithelial airway model. Respir. Res. 13, 8 (2012).
57. Gradon L, Podgorski A. Hydrodynamical model of pulmonary clearance. Chem. Eng. Sci. 44, 741-749 (1989).
58. Sosnowski TR, Gradon L, Podgorski A. Influence of insoluble aerosol deposits on the surface activity of the pulmonary surfactant: a possible mechanism of alveolar clearance retardation? Aerosol Sci. Technol. 32, 52-60 (2000).
59. Brown RA, Schanker LS. Absorption of aerosolized drugs from the rat lung. Drug Metab. Dispos. 11, 355-360 (1983).
60. Tronde A, Norden B, Jeppsson AB et al. Drug absorption from the isolated perfused rat lung - correlations with drug physicochemical properties and epithelial permeability. J. Drug Target 11, 61-74 (2003).
61. Wiedmann TS, Bhatia R, Wattenberg LW. Drug solubilization in lung surfactant. J. Control Release 65, 43-47 (2000).
62. Ibrahim M, Garcia-Contreras L. Mechanisms of absorption and elimination of drugs administered by inhalation. Ther. Deliv. 4, 1027-1045 (2013).
63. Bayard FJ, Thielemans W, Pritchard DI et al. Polyethylene glycol-drug ester conjugates for prolonged retention of small inhaled drugs in the lung. J. Control Release 171, 234-240 (2013).
64. Zhang JY, Wang Y, Prakash C. Xenobiotic-metabolizing enzymes in human lung. Curr. Drug Metab. 7, 939-948 (2006).
65. Baginski L, Tachon G, Falson F, Patton JS, Bakowsky U, Ehrhardt C. Reverse transcription polymerase chain reaction (RT-PCR) analysis of proteolytic enzymes in cultures of human respiratory epithelial cells. J. Aerosol Med. 24, 89-101 (2011).
66. Wang YB, Watts AB, Peters JI, Williams RO 3rd. The impact of pulmonary diseases on the fate of inhaled medicines-a review. Int. J. Pharm. 461, 112-128 (2014).
67. Postma DS, Reddel HK, ten Hacken NH, van den Berge M. Asthma and chronic obstructive pulmonary disease: similarities and differences. Clin. Chest Med. 35, 143-156 (2014).
68. Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment. Ann. Rev. Pathol. 6, 147-163 (2011).
69. Kim CS, Kang TC. Comparative measurements of lung deposition of inhaled fine particles in normal subjects and patients with obstructive airway disease. Am. J. Respir. Crit. Care Med. 155, 899-905 (1997).
70. Geller DE. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir. Care 50, 1313-1322 (2005).
71. Sanchis J, Corrigan C, Levy ML et al. Inhaler devices - from theory to practice. Respir. Med. 107, 495-502 (2013).
72. Newman SP. Principles of metered-dose inhaler design. Respir. Care 50, 1177-1190 (2005).
73. Smyth HD. Propellant-driven metered-dose inhalers for pulmonary drug delivery. Expert Opin. Drug Deliv. 2, 53-74 (2005).
74. Bell J, Newman S. The rejuvenated pressurised metered dose inhaler. Expert Opin. Drug Deliv. 4, 215-234 (2007).
75. Ivey JW, Vehring R, Finlay WH. Understanding pressurized metered dose inhaler performance. Expert Opin. Drug Deliv. doi:10.1517/17425247.174217984683 (2014) (Epub ahead of print).
76. Rubin BK, Fink JB. Optimizing aerosol delivery by pressurized metered-dose inhalers. Respir. Care 50, 1191-1200 (2005).
77. Dalby R, Spallek M, Voshaar T. A review of the development of Respimat Soft Mist Inhaler. Int. J. Pharm. 283, 1-9 (2004).
78. Hochrainer D, Hölz H, Kreher C, Scaffidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J. Aerosol Med. 18, 273-282 (2005).
79. Cordts E, Steckel H. Formulation considerations for dry powder inhalers. Ther. Deliv. 5, 675-689 (2014).
80. Yang MY, Chan JG, Chan HK. Pulmonary drug delivery by powder aerosols. J. Control Release 193, 228-240 (2014).
81. Hoppentocht M, Hagedoorn P, Frijlink HW, de Boer AH. Technological and practical challenges of dry powder inhalers and formulations. Adv. Drug Deliv. Rev. 75, 18-31 (2014).
82. Le Brun PP, de Boer AH, Heijerman HG, Frijlink HW. A review of the technical aspects of drug nebulization. Pharm. World Sci. 22, 75-81 (2000).
83. O'Callaghan C, Barry PW. The science of nebulised drug delivery. Thorax 52, S31-S44 (1997).
84. Rau JL. Design principles of liquid nebulization devices currently in use. Respir. Care 47, 1257-1278 (2002).
85. Westerman EM, Heijerman HG, Frijlink HW. Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients. Expert Opin. Drug Deliv. 4, 91-94 (2007).
86. Claus S, Weiler C, Schiewe J, Friess W. How can we bring high drug doses to the lung? Eur. J. Pharm. Biopharm. 86, 1-6 (2014).
87. Tiddens HA, Bos AC, Mouton JW, Devadason S, Janssens HM. Inhaled antibiotics: dry or wet? Eur. Respir. J. 44, 1308-1318 (2014).
88. McCallion ONM, Taylor KMG, Bridges PA, Thomas M, Taylor AJ. Jet nebulizers for pulmonary drug delivery. Int. J. Pharm. 130, 1-11 (1996).
89. Taylor KMG, McCallion ONM. Ultrasonic nebulizers for pulmonary drug delivery. Int. J. Pharm. 153, 93-104 (1997).
90. Yeo LY, Friend JR, McIntosh MP, Meeusen ENT, Morton DAV. Ultrasonic nebulization platforms for pulmonary drug delivery. Expert Opin. Drug Deliv. 7, 663-679 (2010).
91. Gessler T, Schmehl T, Hoeper MM et al. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur. Respir. J. 17, 14-19 (2001).
92. Rau JL, Ari A, Restrepo RD. Performance comparison of nebulizer designs: constant-output, breath-enhanced, and dosimetric. Respir. Care 49, 174-179 (2004).
93. Hertel SP, Winter G, Friess W. Protein stability in pulmonary drug delivery via nebulization. Adv. Drug Deliv. Rev. doi:10.1016/j.addr.1010.1003 (2014) (Epub ahead of print).
94. O'Riordan TG. Formulations and nebulizer performance. Respir. Care 47, 1305-1313 (2002).
95. McCallion ONM, Taylor KMG, Thomas M, Taylor AJ. Nebulization of fluids of different physicochemical properties with air-jet and ultrasonic nebulizers. Pharm. Res. 12, 1682-1688 (1995).
96. McCallion ONM, Patel MJ. Viscosity effects on nebulisation of aqueous solutions. Int. J. Pharm. 130, 245-249 (1996).
97. McCallion ONM, Taylor KMG, Thomas M, Taylor AJ. The influence of surface tension on aerosols produced by medical nebulisers. Int. J. Pharm. 129, 123-126 (1996).
98. McCallion ONM, Taylor KMG, Thomas M, Taylor AJ. Nebulisation of monodisperse latex sphere suspensions in air-jet and ultrasonic nebulisers. Int. J. Pharm. 133, 203-214 (1996).
99. Najlah M, Parveen I, Alhnan MA et al. The effects of suspension particle size on the performance of air-jet, ultrasonic and vibrating-mesh nebulisers. Int. J. Pharm. 461, 234-241 (2014).
100. Gaspar MM, Bakowsky U, Ehrhardt C. Inhaled liposomes - Current strategies and future challenges. J. Biomed. Nanotechnol. 4, 245-257 (2008).
101. Cipolla D, Gonda I, Chan HK. Liposomal formulations for inhalation. Ther. Deliv. 4, 1047-1072 (2013).
102. Kurmi BD, Kayat J, Gajbhiye V, Tekade RK, Jain NK. Micro- and nano-carrier-mediated lung targeting. Expert Opin. Drug Deliv. 7, 781-794 (2010).
103. Lebhardt T, Roesler S, Beck-Broichsitter M, Kissel T. Polymeric nanocarriers for drug delivery to the lung. J. Drug Del. Sci. Tech. 20, 171-180 (2010).
104. Dailey LA, Kleemann E, Wittmar M et al. Surfactant-free, biodegradable nanoparticles for aerosol therapy based on the branched polyesters, DEAPA-PVAL-g-PLGA. Pharm. Res. 20, 2011-2020 (2003).
105. Dailey LA, Schmehl T, Gessler T et al. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J. Control Release 86, 131-144 (2003).
106. Dailey LA, Kleemann E, Merdan T et al. Modified polyethylenimines as non viral gene delivery systems for aerosol therapy: effects of nebulization on cellular uptake and transfection efficiency. J. Control Release 100, 425-436 (2004).
107. Kleemann E, Dailey LA, Abdelhady HG et al. Modified polyethylenimines as non-viral gene delivery systems for aerosol gene therapy: investigations of the complex structure and stability during air-jet and ultrasonic nebulization. J. Control Release 100, 437-450 (2004).
108. Elhissi AMA, Taylor KMG. Delivery of liposomes generated from proliposomes using air-jet, ultrasonic, and vibratingmesh nebulisers. J. Drug Deliv. Sci. Technol. 15, 261-265 (2005).
109. Elhissi AMA, Faizi M, Naji WF, Gill HS, Taylor KMG. Physical stability and aerosol properties of liposomes delivered using an air-jet nebulizer and a novel micropump device with large mesh apertures. Int. J. Pharm. 334, 62-70 (2007).
110. Zaru M, Mourtas S, Klepetsanis P, Fadda AM, Antimisiaris SG. Liposomes for drug delivery to the lungs by nebulization. Eur. J. Pharm. Biopharm. 67, 655-666 (2007).
111. Kleemann E, Schmehl T, Gessler T, Bakowsky U, Kissel T, Seeger W. Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: formulation aspects and stability. Pharm. Res. 24, 277-287 (2007).
112. Hureaux J, Lagarce F, Gagnadoux F et al. Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel. Eur. J. Pharm. Biopharm. 73, 239-246 (2009).
113. Elhissi AMA, Giebultowicz J, Stec AA et al. Nebulization of ultradeformable liposomes: the influence of aerosolization mechanism and formulation excipients. Int. J. Pharm. 436, 519-526 (2012).
114. Beck-Broichsitter M, Knuedeler MC, Schmehl T, Seeger W. Following the concentration of polymeric nanoparticles during nebulization. Pharm. Res. 30, 16-24 (2013).
115. Geller DE. New liquid aerosol generation devices: systems that force pressurized liquids through nozzles. Respir. Care 47, 1392-1405 (2002).
116. Knoch M, Keller M. The customised electronic nebuliser: a new category of liquid aerosol drug delivery system. Expert Opin. Drug Deliv. 2, 377-390 (2005).
117. Lass JS, Sant A, Knoch M. New advances in aerosolised drug delivery: vibrating membrane nebuliser technology. Expert Opin. Drug Deliv. 3, 693-702 (2006).
118. Katial RK, Reisner C, Buchmeier A, Bartelson BB, Nelson HS. Comparison of three commercial ultrasonic nebulizers. Ann. Allergy Asthma Immunol. 84, 255-261 (2000).
119. Johnson JC, Waldrep JC, Guo J, Dhand R. Aerosol delivery of recombinant human DNase I: in vitro comparison of a vibrating-mesh nebulizer with a jet nebulizer. Respir. Care 53, 1703-1708 (2008).
120. Skaria S, Smaldone GC. Omron NE U22: comparison between vibrating mesh and jet nebulizer. J. Aerosol Med. 23, 173-180 (2010).
121. Kohno M, Matsuoka Y. Microfabrication and drilling using diffraction-free pulsed laser beam generated axicon lens. JSME Int. J. Ser. B 47, 497-500 (2004).
122. Geerken MJ, Groenendijk MNW, Lammertink RGH, Wessling M. Micro-fabricated metal nozzle plates used for water-in-oil and oil-in-water emulsification. J. Memb. Sci. 310, 374-383 (2008).
123. Shen SC, Wang YJ, Chen YY. Design and fabrication of medical micro-nebulizers. Sens. Actuators A 144, 135-143 (2008).
124. Lin CY, Meng HC, Fu C. An ultrasonic aerosol therapy nebulizer using electroformed palladium-nickel alloy nozzle plates. Sens. Actuators A 169, 187-193 (2011).
125. Waldrep JC, Berlinski A, Dhand R. Comparative analysis of methods to measure aerosols generated by a vibrating mesh nebulizer. J. Aerosol Med. 20, 310-319 (2007).
126. Hertel S, Pohl T, Friess W, Winter G. That's cool!- Nebulization of thermolabile proteins with a cooled vibrating mesh nebulizer. Eur. J. Pharm. Biopharm. 87, 357-365 (2014).
127. Hertel S, Pohl T, Friess W, Winter G. Prediction of protein degradation during vibrating mesh nebulization via a high throughput screening method. Eur. J. Pharm. Biopharm. 87, 386-394 (2014).
128. Germershaus O, Schultz I, Lühmann T, Beck-Broichsitter M, Högger P, Meinel L. Insulin-like growth factor-I aerosol formulations for pulmonary delivery. Eur. J. Pharm. Biopharm. 85, 61-68 (2013).
129. Wagner A, Vorauer-Uhl K, Katinger H. Nebulization of liposomal rh-Cu/Zn-SOD with a novel vibrating membrane nebulizer. J. Liposome Res. 16, 113-125 (2006).
130. Behr J, Zimmermann G, Baumgartner R et al. Lung deposition of a liposomal cyclosporine A inhalation solution in patients after lung transplantation. J. Aerosol Med. 22, 121-129 (2009).
131. Gaspar MM, Gobbo O, Ehrhardt C. Generation of liposome aerosols with the Aeroneb Pro and the AeroProbe nebulizers. J. Liposome Res. 20, 55-61 (2010).
132. Beck-Broichsitter M, Rieger M, Reul R, Gessler T, Seeger W, Schmehl T. Correlation of drug release with pulmonary drug absorption profiles for nebulizable liposomal formulations. Eur. J. Pharm. Biopharm. 84, 106-114 (2013).
133. Lynch J, Behan N, Birkinshaw C. Factors controlling particle size during nebulization of DNA-polycation complexes. J. Aerosol Med. 20, 257-268 (2007).
134. Nguyen J, Reul R, Betz T et al. Nanocomposites of lung surfactant and biodegradable cationic nanoparticles improve transfection efficiency to lung cells. J. Control Release 140, 47-54 (2009).
135. Beck-Broichsitter M, Gauss J, Packhaeuser CB et al. Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model. Int. J. Pharm. 367, 169-178 (2009).
136. Beck-Broichsitter M, Kleimann P, Gessler T, Seeger W, Kissel T, Schmehl T. Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the Aeroneb® Pro: formulation aspects and nanoparticle stability to nebulization. Int. J. Pharm. 422, 398-408 (2012).
137. Beck-Broichsitter M, Knuedeler MC, Oesterheld N, Seeger W, Schmehl T. Boosting the aerodynamic properties of vibrating-mesh nebulized polymeric nanosuspensions. Int. J. Pharm. 459, 23-29 (2014).
138. Li Z, Zhang Y, Wurtz W et al. Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J. Aerosol Med. 21, 245-254 (2008).
139. Waters V, Ratjen F. Inhaled liposomal amikacin. Expert Rev. Respir. Med. 8, 401-409 (2014).
140. Beck-Broichsitter M, Schmehl T, Seeger W. Customized vibrating-membrane nozzles for enhanced fluid atomization. Aerosol Sci. Technol. 49, iii-viii (2015).
141. Arzhavitina A, Steckel H. Surface active drugs significantly alter the drug output rate from medical nebulizers. Int. J. Pharm. 384, 128-136 (2010).
142. Baumann R, Glöckl G, Nagel S, Weitschies W. Preparation and characterization of magnetizable aerosols. Eur. J. Pharm. Sci. 45, 693-697 (2012).
143. Najlah M, Vali A, Taylor M et al. A study of the effects of sodium halides on the performance of air-jet and vibrating-mesh nebulizers. Int. J. Pharm. 456, 520-527 (2013).
144. Beck-Broichsitter M, Oesterheld N, Knuedeler MC, Seeger W, Schmehl T. On the correlation of output rate and aerodynamic characteristics in vibrating-mesh-based aqueous aerosol delivery. Int. J. Pharm. 461, 34-37 (2014).
145. Beck-Broichsitter M, Prüfer N, Oesterheld N, Seeger W, Schmehl T. Nebulization of active pharmaceutical ingredients with the eFlow®rapid: impact of formulation variables on aerodynamic characteristics. J. Pharm. Sci. 103, 2585-2589 (2014).
146. Olivier BJ, Sorensen CM, Taylor TW. Scaling dynamics of aerosol coagulation. Phys. Rev. A 45, 5614-5623 (1992).
147. Garrett BC. Ions at the air/water interface. Science 303, 1146-1147 (2004).
148. Ghosal S, Hemminger JC, Bluhm H et al. Electron spectroscopy of aqueous solution interfaces reveals surface enhancement of halides. Science 307, 563-566 (2005).
149. Jungwirth P, Tobias DJ. Specific ion effects at the air/water interface. Chem. Rev. 106, 1259-1281 (2006).
150. Dalla-Bona AC, Schmehl T, Gessler T, Seeger W, Beck-Broichsitter M. Systematic aging of degradable nanosuspension ameliorates vibrating-mesh nebulizer performance. Drug Dev. Ind. Pharm. doi:10.3109/03639045.036303993399 (2014) (Epub ahead of print).
151. Weers JG, Bell J, Chan HK et al. Pulmonary formulations: what remains to be done? J. Aerosol Med. 23, S5-S23 (2010).
152. Forbes B, Asgharian B, Dailey LA et al. Challenges in inhaled product development and opportunities for open innovation. Adv. Drug Deliv. Rev. 63, 69-87 (2011).
153. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int. J. Pharm. 392, 1-19 (2010).
154. Fischer A, Stegemann J, Scheuch G, Siekmeier R. Novel devices for individualized controlled inhalation can optimize aerosol therapy in efficacy, patient care and power of clinical trials. Eur. J. Med. Res. 14, 71-77 (2009).
155. Denyer J, Dyche T. The Adaptive Aerosol Delivery (AAD) technology: Past, present, and future. J. Aerosol Med. 23, S1-S10 (2010).
156. Denyer J, Nikander K, Smith NJ. Adaptive Aerosol Delivery (AAD) technology. Expert Opin. Drug Deliv. 1, 165-176 (2004).
157. Newman S. Improving inhaler technique, adherence to therapy and the precision of dosing: major challenges for pulmonary drug delivery. Expert Opin. Drug Deliv. 11, 365-378 (2014).